PO Box 1488
Warrenville, IL 60555
Phone: 331.248.7888
Email: sidp@affinity-strategies.com
Join Prof Jason Roberts and Dr. Erin McCreary for this episode dedicated to discussing the results of the BLING III trial, which explored the use of continuous versus intermittent infusion of a beta-lactam antibiotic in critically ill patients.
Reference: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial. 10.1001/jama.2024.9779
Jason Roberts, PhD
Jason Roberts is an Australian National Health and Medical Research Council Leadership Fellow at the University of Queensland and a consultant clinical pharmacist at the Royal Brisbane and Women’s Hospital. He is the Director of the University of Queensland Center for Clinical Research and the interim Director of the Herston Infectious Diseases Institute. He is a clinician scientist with a strong interest in research and his principal research theme is the optimization of antimicrobial dosing in critically ill patients. He has authored over 650 published papers and book chapters on this topic, has been awarded over $45 million in grants, and has supervised more than 20 PhD students.
